SATB2 and adenocarcinoma: Moreover, while there were no significant treatment predictive effects of SATB2 expression in I-type adenocarcinoma, it is noteworthy that SATB2-positive I-type cases receiving adjuvant chemotherapy had no recurrences or fatalities during the follow up period.